[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604638":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":31,"responsibleParty":42,"collaborators":10,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":10,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":10,"enrollmentInfo":53,"targetDuration":10,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Pfizer","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with severe alopecia areata.",null,"Determined to start treatment with Litfulo Capsule according to the approved indications of the medicinal product.",[13],"Drug: Litfulo",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Litfulo","as provided in real world practice.",[9],[21],"Ritlecitinib tosylate (ATC code: L04AF08)",[23],{"name":24,"affiliation":5,"role":25},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[27],{"name":24,"role":28,"phone":29,"phoneExt":10,"email":30},"CONTACT","1-800-718-1021","ClinicalTrials.gov_Inquiries@pfizer.com",[32],{"facility":5,"status":33,"city":34,"state":10,"zip":10,"country":35,"countryCode":10,"cosmosGeoPoint":36,"geoPoint":41,"contacts":10},"RECRUITING","Seoul","South Korea",{"type":37,"coordinates":38},"Point",[39,40],126.9784,37.566,{"lat":40,"lon":39},{"type":43,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100604638","a-study-to-learn-about-litfulo-capsule-in-people-with-severe-alopecia-areata-in-routine-clinical-practice-100604638",false,"NCT07152119","A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.","KOREAN POST MARKETING SURVEILLANCE FOR LITFULO CAPSULE","Inclusion Criteria:\n\nPatients with severe alopecia areata who have been determined to start treatment with Litfulo Capsule according to the approved indications of the medicinal product Treatment of severe alopecia areata in adults and adolescents 12 years or older Evidence of a personally signed and dated informed consent document indicating that the patient or their parent(s)\u002Flegal guardian, if applicable, have been informed of all pertinent aspects of the study","ALL","12 Years",{"count":54,"type":55},3000,"ESTIMATED","OBSERVATIONAL","The purpose of this observation study is to learn about the safety and effects of the study medicine (called Litfulo) for the potential treatment of Severe Alopecia Areata.",[59],"Severe Alopecia Areata",[17,61,62],"Litfulo capsule","Ritlecitinib tosylate","2026-05-14",{"date":65,"type":66},"2026-05-18","ACTUAL",{"date":68,"type":66},"2025-08-27",{"date":70,"type":55},"2030-03-23",{"name":5,"class":6},1]